Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy

PHASE3UnknownINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

September 30, 2010

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Celecoxib

Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.

DRUG

Placebo

One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.

Trial Locations (13)

413 45

Department of Pulmonary Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg

551 85

Section of Pulmonary Medicine, Ryhov County Hospital, Jönköping

391 85

Section of Pulmonary Medicine and Allergology, County Hospital of Kalmar, Kalmar

581 85

Department of Pulmonary Medicine, University Hospital, Linköping

221 85

Department of Pulmonary Medicine and Allergy, Lund University Hospital, Lund

205 02

Section of Pulmonary Medicine, Malmö University Hospital, Malmo

701 85

Department of Pulmonary Medicine, Örebro University Hospital, Örebro

541 85

Department of Medicine, Skövde Hospital/KSS, Skövde

461 85

Department of Medicine, Trollhättan Hospital/NÄL, Trollhättan

451 80

Department of Medicine, Uddevalla Hospital, Uddevalla

901 85

Department of Pulmonary medicine, Umeå University Hospital, Umeå

751 85

Department of Pulmonary Medicine and Allergology, Uppsala University Hospital, Uppsala

SE-27182

Department of Medicine, Ystad Hospital, Ystad

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Swedish Lung Cancer Study Group

NETWORK

collaborator

Pfizer

INDUSTRY

lead

University Hospital, Linkoeping

OTHER